FMP

FMP

Enter

RGNX - REGENXBIO Inc.

photo-url-https://images.financialmodelingprep.com/symbol/RGNX.png

REGENXBIO Inc.

RGNX

NASDAQ

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

5.39 USD

-0.025 (-0.464%)

About

ceo

Mr. Curran M. Simpson M.S.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

CIK

0001590877

ISIN

US75901B1070

CUSIP

75901B107

Address

9804 Medical Center Drive

Phone

240 552 8181

Country

US

Employee

353

IPO Date

Sep 17, 2015

Key Executives

Name

Title

Pay

Year Born

Craig Malzahn

Executive Vice President, Product Develo...

0

N/A

Dr. Ram Palanki Pharm.D.

Executive Vice President of Commercial S...

0

1977

Mr. Mitchell Chan M.B.A.

Executive Vice President & Chief Financi...

0

1981

Mr. Patrick J. Christmas II, J.D.

Executive Vice President & Chief Legal O...

1.11M

1971

Ms. Shiva G. Fritsch

Chief Communications & People Officer

0

N/A

Dr. Olivier Danos Ph.D.

Executive Vice President & Chief Scienti...

778.85k

1958

Mr. Curran M. Simpson M.S.

President, Chief Executive Officer & Dir...

698.6k

1962

Dr. Stephen Pakola M.D.

Executive Vice President & Chief Medical...

674.05k

1969

As of December 31, 2024, the total employee count stands at 353, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep